Progression-free survival was longer with nivolumab plus ipilimumab than with chemotherapy among patients who had not previously received systemic treatment for MSI-H or dMMR metastatic colorectal cancer. #NEJM #medsky #news #meded #oncology

Read more
https://www.nejm.org/doi/full/10.1056/NEJMoa2402141